AdeTherapeutics Retains Financial Advisor to Explore Strategic Options

Fibrosis Platform and Pipeline Attracting Broad Interest from Pharmaceutical and Mid-to-Large Biotech

AdeTherapeutics Retains Financial Advisor to Explore Strategic Options

AdeTherapeutics, Inc.Sanj Singh, +1-306-261-5189orBroadPRTracy Wemett, +1-617-868-5031

AdeTherapeutics, Inc., a world leader in developing products that reduce or scar tissue (adhesion) complications related to surgery, today announced the company has retained Beal Advisors, a boutique investment bank located in San Francisco, to conduct a formal process to evaluate strategic options that have become available to the company.

“Our novel wound healing modulation approach which has created a deep pipeline of products in women’s health, neurosurgery and ophthalmology with potential in plastics and orthopedics, along with animal health, has caught the attention of companies looking for a fibrosis platform that could have multiple applications,” commented Sanj Singh, CEO of AdeTherapeutics. “We have been approached by a number of large pharmaceutical and biotech companies that are interested in our technology as well as a number of venture capital firms interested in a possible investment, thus we thought now is the time to formalize a strategic process with the addition of Beal Advisors.”

AdeTherapeutics is leveraging its novel and rapid wound healing discovery to bring first-in-class therapeutic and device products into clinical development. The company is setting the standard of care for surgeons to prevent adhesions in ophthalmology as well as gynaecology, neurosurgery (joint collaboration with Royal Biomedical to address pain and failed back surgery syndrome) and general surgery.

“We are excited to be working with AdeTherapeutics in investigating and evaluating the numerous opportunities the company has in front of them,” explained Georgia Erbez, managing director of Beal Advisors in San Francisco. “They have a novel technology that lends itself to a variety of strategic options, including Series A financing, therapeutic or regional partnerships, merger with a like-size company or whole company acquisition. We have been brought in to assist the management team to evaluate these opportunities, maximize value and ensure that the products reach the market.”

Beal Advisors, established in 2008, is a boutique investment banking firm providing strategic advisory, mergers and acquisition advisory, business development and financing services to public and private companies in the life sciences industry. Our principals each have over 20 years of investment banking and financial advisory services. Through Beal Capital Partners, Beal offers fund placement advisory services to leading venture capital and hedge funds. For additional information, visit .

AdeTherapeutics is a privately held market driven and clinical-stage product development company located in Canada. The company’s vision is to be the worldwide leader in developing products that deal with complications related to surgery. Core competencies lie in its ability to translate clinical insight to the lab and then to bedside. The team consists of PhD/MD surgeons, clinical development expertise and regulatory with C-level management, board and advisory board members to add significant value – designed by surgeons for surgeons and their patients. An extensive portfolio of patented and patent pending assets position the company to establish standard of care in large unmet medical need areas within the surgical fields of gynecology, general, neurosurgery (failed back surgery syndrome), ophthalmology and dermal/plastics. For more information, visit: .

Suggested Articles

The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test with Roche’s checkpoint inhibitor Tecentriq.

Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones.

Harvard University scientists are teaming up with the Guangzhou Institute of Respiratory Disease with a $115 million boost from China.